Business · India Bureau
Mankind Pharma partners with Chinese firm to expand insulin analogue portfolio
The pharmaceutical manufacturer has inked an agreement to market insulin analogues in India, signalling its intent to strengthen its presence in the injectable diabetes therapeutics segment. The deal is part of a broader strategy to pursue additional collaborations with Chinese drug makers.
LSN India ·
Mankind Pharma has entered into a partnership with a Chinese pharmaceutical company to market insulin analogues across India, bolstering its offerings in the high-growth diabetes treatment market. The agreement represents the company's latest move to build its in-licensed drug portfolio while establishing greater penetration in injectable diabetes therapies, a segment that has seen rising demand amid increasing prevalence of diabetes in the country.
The collaboration underscores Mankind Pharma's strategy of diversifying its product range through strategic partnerships. By tapping into Chinese pharmaceutical expertise and innovation, the company aims to accelerate its entry into newer therapeutic categories and enhance its competitive position in the Indian market.
The company has signalled its openness to further partnerships with Chinese pharmaceutical manufacturers as part of its expansion roadmap. Such licensing agreements allow Indian pharmaceutical firms to access innovative molecules and formulations developed by international counterparts, enabling faster market entry without bearing the full burden of research and development costs.
The move comes amid intensifying competition in India's diabetes care market, where both domestic and multinational players are vying for share through product differentiation and expanded therapeutic portfolios. Insulin analogues, which offer improved efficacy and convenience compared to conventional insulin formulations, represent a key growth segment within this space.